Marker Therapeutics, Inc.
MRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $28 | $48 | $22 | $73 |
| - Cash | $19 | $15 | $12 | $42 |
| + Debt | $0 | $0 | $8 | $12 |
| Enterprise Value | $9 | $33 | $18 | $42 |
| Revenue | $7 | $3 | $4 | $1 |
| % Growth | 99.1% | -5.8% | 183% | – |
| Gross Profit | -$7 | -$7 | -$8 | -$2 |
| % Margin | -104.3% | -214.6% | -240.6% | -154.7% |
| EBITDA | -$11 | -$12 | -$17 | -$39 |
| % Margin | -168.7% | -356.1% | -483.9% | -3,118% |
| Net Income | -$11 | -$8 | -$30 | -$42 |
| % Margin | -162.8% | -248.8% | -851.9% | -3,372.7% |
| EPS Diluted | -1.19 | -1.93 | -3.58 | -5.47 |
| % Growth | 38.3% | 46.1% | 34.6% | – |
| Operating Cash Flow | -$11 | -$16 | -$27 | -$27 |
| Capital Expenditures | $0 | $0 | $0 | -$3 |
| Free Cash Flow | -$11 | -$16 | -$27 | -$30 |